SLIT2 modulates leukaemic cell proliferation and stromal support in acute myeloid leukaemia models.
It is demonstrated that SLIT2 may act as a tumour suppressor, while SLIT2 loss impairs myeloid terminal differentiation, suggesting that SLIT2 signalling could serve as a potential therapeutic axis in AML.